Efdoralprin alfa improves endpoints in alpha-1 antitrypsin deficiency-related emphysema

ORLANDO — Compared with the current standard of care for patients with alpha-1 antitrypsin deficiency-related emphysema, investigational efdoralprin alfa showed better outcomes and similar safety, according to data presented here.This investigational therapy from Sanofi “is a recombinant human [alpha-1 antitrypsin-fragment crystallizable] fusion protein,” according to a company